

**2024 ISV ANNUAL CONGRESS
SATELLITE CONFERENCE: CHINA DAY
PROGRAM
会议议程**

**Onsite Registration (Maximum 70 participants)
现场注册（限 70 人）**

Conference Hotel: SEOUL DRAGON CITY

Room: Shilla 1 + 2

호텔: 서울드래곤시티

会议酒店: 首尔龙城酒店

Address: 95 CHEONGPA-RO 20-GIL, YONGSAN-GU

(주)서부터엔디 / 서울시 용산구 청파로 20 길 95

地址: 韩国首尔市龙山区青坡路 20 街 95 号

Date

Time

Onsite Check-in

2024-10-20

13:30 -17:00

Registration starts at 12:30

Entrance of Shilla 1 + 2

组委会 (Organizing Committee) : Anna Du, Baomin Jiang, Qihan Li, Sam Li, Shan Lu, Bin Wang, Yuan Yuan, Tao Zhu.

主办单位: 上海市生物医药科技产业促进中心, International Society for Vaccines

Organizer: Shanghai Center of Biomedicine Development, International Society for Vaccines

协办单位: 南京波士南健康科技有限公司

Co-organizer: Nanjing Bosnan Health Technology Co., Ltd.

CONTACT:

王宁逸 Ningyi.wang@bosnan.com

蒋斯元 Siyuan.jiang@bosnan.com

Sunday, 20th October 2024	
Room Shilla 1 + 2, Dragon City Hotel, Seoul, South Korea	
12:30-17:30	REGISTRATION 现场注册
13:30-13:45	WELCOME BY ISV PRESIDENT: Linda Klavinskis, King's College London, UK 欢迎致辞: 琳达·S·克拉文斯基, ISV 主席, 伦敦国王学院
	Organizers Remarks: Anna DU, Bill & Melinda Gates Foundation; Shan LU, UMASS Chan Medical School, USA; 组委会致辞: Anna Du, 比尔及梅琳达·盖茨基金会; 卢山, 马萨诸塞州陈医学院;
	Session One Chairs: Bin WANG, Fudan University; Sam LI, ChStone ;
13:45	Overall introduction of SCBD and Shanghai Biomedical industry Xiao SUN, Senior Director of Platform Partnership Department, Shanghai Center of Biomedicine Development (SCBD)
14:05	Introduction of Shanghai Center for Drug Evaluation and Inspection Gang LI, Shanghai Center for Drug Evaluation and Inspection
14:20	China Vaccine Landscape Yuan YUAN, China Country Representative, Business & Alliance Management, PATH
14:40	Pathogen Distribution And Pneumococcus Disease Burden Of Clinical Diagnosed Pneumonia Among Children, A Multi-Center Case-Control Study Yi ZHANG, Huashan Hospital Affiliated with Fudan University
14:55	Next Peumocccocal Disease Vaccines Tao ZHU, Co-founder, Executive Director and CSO, CanSino
15:10	Thermo-stable mRNA Vaccine Yuanqing LIU, CSO, Immorna
15:25-16:00	Tea Break
	Session Two Chairs: Tao ZHU, Co-founder, Executive Director and CSO, CanSino; Baoming JIANG, US Centers for Disease Control and Prevention (US CDC)
16:00	The Technical Design Of Vaccine With Virus-Like Structure (VLS) Against Sars-Cov-2 Variants Jingjing ZHANG, Professor, Wei Rui Biotechnology(Kunming)/Shandong Weigao Litong Biological Products(Weihai)
16:15	Rapid Evaluation of Potency of Vaccine Adjuvants Using a Photoconversion Mouse Model Bin WANG, Fudan University
16:30	Novel Adjuvant Vaccine Development And Large Scale-Up Production Dexiang CHEN, Founder, Maxvax
16:45	Integrated mRNA Product Development-A Collaborative Way to Deliver Hang YU, Co-founder, CEO, RNACure
17:00	To be added
17:15	Group Photo and Closing OF China Day CONFERENCE

ISV ANNUAL CONGRESS, 21-23 OCTOBER 2024
DRAGON CITY HOTEL, SEOUL, SOUTH KOREA
ORAL PROGRAM
MONDAY 21 OCTOBER 2024

08:00-10:00	REGISTRATION	(Hanra Foyer)
09:00-10:00	WELCOME COFFEE <i>Sponsored by Afrigen Biologics & Vaccines</i>	(Hanra Foyer)
10:00-10:10	OPENING SESSION: Session Chair: Joon Haeng Rhee, Chonnam National University, South Korea INTRODUCTION OF THE 2024 ISV ANNUAL CONGRESS & CO-CHAIRS: Margaret Liu, ProTherImmune & Karolinska Institutet, USA & Sweden Shan Lu, UMASS Chan Medical School, USA; Jerome Kim, International Vaccine Institute (IVI), South Korea; Ken Ishii, University of Tokyo, Japan WELCOME BY ISV PRESIDENT: Linda Klavinskis, King's College London, UK	(Hanra 1 & 2)
10:10-10:40	STANLEY PLOTKIN LECTURE: Session Chair: Joon Haeng Rhee, Chonnam National University, South Korea INTRODUCTION OF STANLEY PLOTKIN LECTURE & 2024 SPEAKER: Linda Klavinskis, King's College London, UK STANLEY PLOTKIN LECTURE 2024 SPEAKER: Advancing Vaccine End-to-End Capabilities (AVEC) in Africa: A Model for Sustainable Regional Vaccine Manufacturing Jerome Kim, International Vaccine Institute (IVI), South Korea	(Hanra 1 & 2)
10:40-12:00	PLENARY SESSION 1: CLIMATE CHANGE AND EMERGING INFECTIONS Session Chairs: Jeffrey Ulmer, TechImmune LLC, USA; Ken Ishii, University of Tokyo, Japan	(Hanra 1 & 2)
10:40-11:05	Climate and Infectious Diseases: Past, Present and Future Axel Timmermann, Pusan University, South Korea	
11:05-11:30	Clinical Advances in Vaccines for Blood-Stage Malaria Simon Draper, University of Oxford, UK	
11:30-11:45	Lung Eosinophil Recruitment and Type 2 Host Immune Responses in Vaccinated Mice is Non-Pathological and Correlates with Protection During Influenza Infection in Mice with Infection Permissive or Sterilizing Immunity Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA	
11:45-12:00	Peripheral Co-Delivery of Plasmid-Encoded Mucosal Chemokine CCL27 Enhances Mucosal Immunity and Supports Protection from Heterologous SARS-CoV-2 and H5N1 Influenza Challenges in Vivo Ebony N. Gary, The Wistar Institute, USA	
12:00-13:30	LUNCH <i>Sponsored by Pfizer</i>	(Hanra 1 & 2)
12:15-13:25	<p style="text-align: center;">Cutting Edge: AI/ML and Computational Vaccinology Workshop Organized by EpiVax, Inc.</p> Session Chairs: Joon Haeng Rhee, Chonnam National University, South Korea; Manon Cox, NextWaveBio, USA Yoshimasa Takahashi, Director of the Research Center for Drug and Vaccine Development at NIID Japan Anne De Groot, Founder and CSO of EpiVax, Inc. Chaok Seok, Professor in the Department of Chemistry, Seoul National University / CEO of Galux Inc.	(Hanra 3)

13:30-14:50	PLENARY SESSION 2: VACCINES WITH BROAD IMPACT (Hanra 1 & 2) Session Chairs: Margaret Liu, <i>ProTherImmune & Karolinska Institutet, USA & Sweden;</i> Lars Frelin, <i>Karolinska Institutet, Sweden</i>		
13:30-13:55	Vaccines for TB and HIV: Opportunity and Access Nina Russell , <i>Gates Foundation, USA</i>		
13:55-14:20	A Vaccine to Prevent Congenital CMV: How Close Are We? Sallie Permar , <i>Weill Cornell Medicine, USA</i>		
14:20-14:35	Development of Parenteral Vaccines for Global Control of Rotavirus Diarrhea in Children: Progress and Update Baoming Jiang , <i>Centers for Disease Control and Prevention, (CDC), USA</i>		
14:35-14:50	Long-Term Impact of Rotavirus Vaccination on All-Cause and Rotavirus-Specific Gastroenteritis and Strain Distribution in Central Kenya: An 11-Year Interrupted Time-Series Analysis Ernest Wandera , <i>Kenya Medical Research Institute, (KEMRI), Kenya</i>		
15:00-15:30	COFFEE BREAK <i>Sponsored by Arcturus Therapeutics</i> (Hanra Foyer)		
15:30-17:20	Concurrent Session: Bright Sparks in Vaccinology: PhD Students Location: Rendezvous Room 2nd Floor Session Chairs: Linda Klavinskis , <i>King's College London, UK</i> Jean Boyer , <i>Agenta Therapeutics, USA</i> (See pages following program for details)		
15:30-17:30	CONCURRENT SESSION 1 (Hanra 1) VIRAL VACCINES OF CONTEMPORARY INTEREST Session Chairs: Mark Connors , <i>NIH/NIAID, USA</i> Danilo Casimiro , <i>Sanofi, USA</i>	CONCURRENT SESSION 2 (Hanra 2) STRATEGIES FOR IMPROVED PROTECTION Session Chairs: Kai Dallmeier <i>KU Leuven, Belgium</i> Simon Draper , <i>University of Oxford, UK</i>	CONCURRENT SESSION 3 (Hanra 3) VACCINES AGAINST CHALLENGING TARGETS <i>Sponsored by Pfizer</i> Session Chairs: Petro Terblanche , <i>Afrigen Biologics & Vaccines, South Africa</i> Tim Hirst , <i>GPN Vaccines, Australia</i>
15:30-15:55	PIV5-Vectored RSV and COVID-19 Intranasal Vaccines Show Great Promise in Clinical Studies Hong Jin , <i>Blue Lake Biotechnology, USA</i>	Enhancing HIV Broadly Neutralizing Antibodies Through Multistate Affinity Optimization Joseph Jardine , <i>Scripps Research Institute, USA</i>	Progress Toward Development of a Human Lyme Disease Vaccine James Baber , <i>Pfizer Vaccine Research and Development, Australia</i>
15:55-16:10	Safety and Immunogenicity of Ad5-nCoV Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-label, Phase 4, Randomised Trial Hui Zheng , <i>Southeast University, China</i>	Controlling Antibody Breadth to Viral Antigens Yoshimasa Takahashi <i>National Institute of Infectious Diseases, Japan</i> (15:55-16:20)	Development of an Anti-Tauopathy Mucosal Vaccine Specifically Targeting Pathologic Conformers Shee Eun Lee , <i>Chonnam National University, South Korea</i> (15:55-16:20)
16:10-16:25	Analysis of Adverse Events in Immunocompromised Individuals Following Moderna COVID-19 Vaccination: Insights From 701,070 Reported Cases (December 2020 to June 2023) Veronica Urdaneta , <i>Moderna, Inc., USA</i>	K3-SPG-Mediated Long-Term Protection Against Viral Infection Asuka Tobuse <i>University of Tokyo, Japan</i> (16:20-16:35)	Transfection of the Apicomplexan Parasite <i>Theileria Parva</i> Sporozoites: Towards CRISPR/Cas Gene Editing for Vaccine Development Ethel Webi , <i>University of Nairobi, Kenya</i> (16:20-16:35)

16:25-16:40	A First-In-Man Placebo Controlled, Randomized, Double-Blind, Phase I Clinical Trial of a Multi Antigen SARS-CoV DNA Vaccine Delivered by In Vivo Electroporation as a Booster Dose, Following Three Doses of Spike-Based mRNA Vaccines Soo Aleman <i>Karolinska Institutet, Sweden</i>	Broad Filovirus Protection via NK Cell Activation and Neutrophil Phagocytosis in Mice Induced by a YF17D-Vectored Sudan Virus Vaccine Lara Kelchtermans, <i>KU Leuven, Belgium</i> (16:35-16:50)	Vaccine Development Against Multidrug Resistant A. baumannii Infection Yun Shi <i>West China Hospital, China</i> (16:35-16:50)
16:40-16:55	Increased Potency and Breadth of Protection Conferred by a Next-Generation Pre-Emptive SARS-CoV-2 Vaccine Targeting both B and T Cell Responses Jeffrey Ulmer, <i>TechImmune LLC, USA</i>	A VLP-like Polio Vaccine Candidate Produced on Insect Cell are Safe and Immunogenic in Human Adults Qiaoling Yan, <i>CanSino Biologics Inc., China</i> (16:50-17:05)	An Improved Theileria Parva Sporozoite Seroneutralization Assay to Evaluate Vaccine Candidates for East Coast Fever Hannah Chege, <i>University of Nairobi, Kenya</i> (16:50-17:05)
16:55-17:10	Rational Immunogen Design for a Pan-Betacoronavirus Vaccine Mihai Azoitei, <i>Duke Human Vaccine Institute, USA</i>	Immunogenetic and Molecular Epidemiological Study of Small Ruminant Lentiviruses in Mongolia Davaasuren Nergui, <i>Mongolian University of Life Sciences, Mongolia</i> (17:05-17:20)	Two-year Antibody Persistence and Safety of a Single-Dose Live-Attenuated Chikungunya Virus Vaccine (VLA1553) in Adults Aged 18 Years and Above Susanne Eder-Lingelbach, <i>Valneva Austria GmbH</i> (17:05-17:20)
17:10-17:25	Safety and Efficacy Tests of Brucella Abortus Strain 104M in Human Volunteers Huimin Wang, <i>China Agricultural University, China</i>	Pilot-Scale Production of Inactivated Monoglycosylated Split H1N1 Influenza Virus Vaccine Provides Cross-Strain Protection Against Influenza Viruses JR Chen, <i>RuenHuei biopharma, China</i> (17:20-17:35)	
17:30-20:00	POSTER SESSION 1 (Shilla 1-5)		
18:00-18:20	ISV CONGRESS AWARDS CEREMONY (Shilla 1-5) Nina Russell, <i>Gates Foundation, USA</i> Linda Klavinskis, <i>ISV President, King's College London, UK</i>		
18:00-20:00	WELCOME RECEPTION <i>Sponsored by Epivax, Inc.</i> (Shilla 1-5/Hanra/Shilla Foyers/Hanra 1)		

TUESDAY 22 OCTOBER 2024			
08:00-08:30	MORNING COFFEE <i>Sponsored by SK bioscience</i> (Hanra Foyer)		
08:30-08:55	MORNING SESSION: (Hanra 1 & 2) Session Chair: Nina Russell , <i>Gates Foundation, USA</i> KEYNOTE SPEAKER: Targeting Airway Immunity with Novel Vaccine Strategies Peter Lawaetz Andersen , <i>Novo Nordisk Foundation, Denmark</i>		
08:55-10:15	PLENARY SESSION 3: AI AND MACHINE LEARNING FOR VACCINE R&D (Hanra 1 & 2) Session Chairs: Xavier Saelens , <i>VIB-Ghent University, Belgium</i> ; Jason McLellan , <i>The University of Texas at Austin, USA</i>		
08:55-09:20	AI-Immunology™ – A New Era in Vaccine Development Andreas Holm Mattsson , <i>Evaxion Biotech, Denmark</i>		
09:20-09:45	Digital Innovations in the Development of Next-Generation Influenza Vaccines Danilo Casimiro , <i>Sanofi Vaccines R&D, USA</i>		
09:45-10:00	VIOLIN in the Era of AI: An Integrative Vaccine Knowledgebase and Analysis System Jungkuk Hur , <i>University of North Dakota, USA</i>		
10:00-10:15	Artificial and Human Intelligences Combined: Removal of Inhibitory Sequences Improves Vaccine Immunogenicity and Efficacy Guilhem Richard , <i>EpiVax, Inc., USA</i>		
10:15-10:45	COFFEE BREAK <i>Sponsored by GPN Vaccines</i> (Hanra Foyer)		
10:45-12:25	Concurrent Session: Bright Sparks in Vaccinology: Early Career Researchers Location: Rendezvous Room 2nd Floor Session Chairs: Linda Klavinskis , <i>King's College London, UK</i> Frédéric Tangy <i>Oncovita - Institut Pasteur, France</i> (See pages following program for details)		
10:45-12:30	CONCURRENT SESSION 4 (Hanra 1) MUCOSAL VACCINES Session Chairs: Bin Wang , <i>Advaccine Biopharmaceuticals</i> <i>Suzhou Co., Ltd., China</i> Yoshimasa Takahashi , <i>National Institute of Infectious Diseases,</i> <i>Japan</i>	CONCURRENT SESSION 5 (Hanra 2) THE MYSTERY OF MERS: VACCINES & IMMUNOLOGY <i>Co-Organized with</i> IVI Session Chairs: Baik Lin Seong <i>Vaccine Innovative Technology Alliance Korea (VITAL-Korea),</i> <i>South Korea</i> Jerome Kim , <i>International Vaccine Institute (IVI),</i> <i>South Korea</i>	CONCURRENT SESSION 6 (Hanra 3) ROUNDTABLE: REGULATORY ISSUES FOR VACCINE DEVELOPMENT Session Chairs: Neil Almond , <i>Medicines and Healthcare products Regulatory Agency (MHRA),</i> <i>UK</i> Shan Lu , <i>UMASS Chan Medical School,</i> <i>USA</i>
10:45-11:10	Inhaled SARS-CoV-2 Vaccine for Single-Dose Dry Powder Aerosol Immunization Guanghui Ma , <i>Chinese Academy of Sciences,</i> <i>China</i>	The International Vaccine Institute (IVI) and the Middle East Respiratory Syndrome in Korea Jerome Kim , <i>International Vaccine Institute (IVI),</i> <i>South Korea</i> (10:45-10:55)	PANEL MEMBERS: Corey Casper , <i>University of Washington,</i> <i>USA</i>

11:10-11:35	<p>A Hitchhiker's Guide to Mucosal Immunity: Harnessing Albumin Hitchhiking for Enhanced Intranasal Vaccine Uptake and Efficacy</p> <p>Brittany Hartwell, <i>University of Minnesota, USA</i></p>	<p>Development of the ChAdOx1 MERS Vaccine</p> <p>Sarah Gilbert, <i>University of Oxford, UK</i></p> <p>(10:55-11:20)</p>	<p>SungHee Hong, <i>SK bioscience, South Korea</i></p> <p>Tao Zhu, <i>CanSinoBIO, China</i></p> <p>(10:45-11:45)</p>
11:35-11:50	<p>Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform</p> <p>Venigalla Rao <i>The Catholic University of America, USA</i></p>	<p>Rise in Broadly Cross-Reactive Adaptive Immunity Against Human β-Coronaviruses in MERS-Recovered Patients During the COVID-19 Pandemic</p> <p>Nam-Hyuk Cho, <i>Seoul National University College of Medicine, South Korea</i></p> <p>(11:20-11:45)</p>	<p>LATE BREAKER ABSTRACT SESSION</p>
11:50-12:05	<p>Harnessing Innate Immune Memory for Enhancing Vaccine Efficacy: New Molecular Mechanisms Controlling Memory Establishment and Persistence</p> <p>Diana Boraschi <i>SUAT, China</i></p>	<p>Development of MERS-CoV Vaccine Using an Attenuated and Highly Effective Recombinant Vesicular Stomatitis Virus (rVSV) System</p> <p>Seung Ho Choo <i>CREO SG Vaccine Institute, South Korea</i></p> <p>(11:45-12:05)</p>	<p>Lipid Formulated Plasmid DNA Drives Robust Innate Immune Activation to Promote Adaptive Immunity</p> <p>David Weiner, <i>The Wistar Institute, USA</i></p> <p>(11:45-12:00)</p>
12:05-12:20	<p>Heterologous Prime/Boost Immunization with Newcastle Disease Virus and Modified Vaccinia Virus Ankara Vectors as an Improved and Effective Strategy Against SARS-CoV-2 Infection</p> <p>Juan Garcia-Arriaza <i>Centro Nacional de Biotecnología, Spain</i></p>	<p>Purification and Characterization of Bivalent Vaccine Candidate Against SARS-CoV-1 and MERS-CoV Expressed as Inclusion Bodies in <i>E. coli</i></p> <p>Rahul Ahuja, <i>Translational Health Science and Technology Institute (THSTI), India</i></p> <p>(12:05-12:20)</p>	<p>An Intranasal Newcastle Disease Virus (NDV)-Based SARS-CoV-2 Omicron Vaccine Elicits Protective Immune Responses in Mice and Hamsters</p> <p>Stefan Slamanig, <i>Icahn School of Medicine at Mount Sinai, USA</i></p> <p>(12:00-12:15)</p>
		<p>Protein Nanoparticle Vaccines Induce Potent Neutralizing Antibody Responses Against MERS-CoV</p> <p>Cara Chao, <i>University of Washington, USA</i></p> <p>(12:20-12:35)</p>	<p>Safety and Immunogenicity of a SARS-CoV-2 mRNA Virus-like Particle Vaccine in Adults 18 years of Age and Older in a Phase 1 Randomized Clinical Trial</p> <p>Lee-Jah Chang, <i>AstraZeneca, USA</i></p> <p>(12:15-12:30)</p>
12:30-14:00	<p>LUNCH Sponsored by Vaxxas (Hanra 1 & 2)</p>		

12:45-14:00	Current Status and Future Prospects of New Vaccine Development Workshop (Hanra 3) <i>Organized by Global Vaccine Leading Technology Center (GVLTC)</i> Workshop Chair: Jeong-Taek Woo, GVLTC - Introduction to the GVLTC (12:45-12:50) Kee-Jong Hong, Gachon University - Global Pandemic Preparedness and Vaccine R & D in Korea (12:50-13:15) Jae-Chul Pyun, Yonsei University - Rapid Screening of Target Antigenic Sites for SARS-CoV-2 Vaccine Development Using Fv-Antibody Library (13:15-13:40) Myung-shin Lee, Eulji University – Dengue Vaccine Development: Codon-Pair Deoptimization and IFNAR2 KO Pig Model (13:40-14:00)
13:30-15:00	POSTER SESSION 2 (Shilla 1-5)
14:00-15:00	ISV ANNUAL GENERAL MEETING (Hanra 1) Meeting Chair: Linda Klavinskis, King's College London, UK
15:00-15:30	COFFEE BREAK <i>Sponsored by BioNTech</i> (Hanra Foyer)
15:30-17:35	PLENARY SESSION 4: DELIVERY & NEW ADJUVANTS (Hanra 1 & 2) Session Chairs: Lakshmi Krishnan, National Research Council Canada (NRC); Sarah Gilbert, University of Oxford, UK
15:30-15:55	Vaccines for Older Adults: The Role of Adjuvants Birgit Weinberger, University of Innsbruck, Austria
15:55-16:20	A Gaps-and-Needs Analysis of Vaccine R&D in Africa: Recommendations to Improve the Research Infrastructure (RECORDING) Nicaise Ndembi, Africa Centres for Disease Control and Prevention (Africa CDC), Ethiopia
16:20-16:35	Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Michael Sumner, Inovio Pharmaceuticals, USA
16:35-16:50	Effect of Adjuvants on the Efficacy of an Izumo1-based Immun contraceptive Vaccine in Mice Harm Hogenesch, Purdue University, USA
16:50-17:05	Combination Adjuvants Targeting Nucleic Acid Sensors for Cancer Immunotherapy Burcu Temizoz, The Institute of Medical Science, The University of Tokyo (IMSUT), Japan
17:05-17:20	Novel Fully Synthetic Saponin-Based Vaccine Adjuvant for Protein-based Vaccines ChunKai Chang, ImmunAdd, Taiwan
17:20-17:35	Heroin and Fentanyl Vaccines Adjuvanted with Army Liposome Formulation Essie Komla, Henry M. Jackson Foundation, USA
18:00	PICK UP FOR GALA DINNER (TICKETS REQUIRED)

WEDNESDAY 23 OCTOBER 2024			
08:00-08:30	MORNING COFFEE <i>Sponsored by CanSinoBIO</i> (Hanra Foyer)		
08:30-08:55	MORNING SESSION: (Hanra 1 & 2) Session Chair: Manon Cox, <i>NextWaveBio, USA</i> KEYNOTE SPEAKER: Vaccines for Emerging Viruses Albert Osterhaus, <i>University of Veterinary Medicine Hannover (TiHo), Germany</i>		
08:55-10:00	PLENARY SESSION 5: THERAPEUTIC VACCINES AGAINST CANCER (Hanra 1 & 2) Session Chairs: David Weiner, <i>The Wistar Institute, USA</i> ; Anne De Groot, <i>EpiVax Inc., USA</i>		
08:55-09:20	A Synthetic Booster Vaccine for Chimeric Antigen Receptor T cells Leyuan Ma , <i>University of Pennsylvania, USA</i>		
09:20-09:45	mRNA-4157/V940, Individualized Neoantigen Therapy: mRNA Therapeutics Coming of Age in Cancer Kaku Saito , <i>Moderna, Japan</i>		
09:45-10:00	Recent Developments of an Improved Measles Vaccine Vector for Cancer Immunotherapy and New Prophylactic Vaccines Frederic Tangy , <i>Oncovita - Institut Pasteur, France</i>		
10:00-10:30	COFFEE BREAK <i>Sponsored by EuBiologics</i> (Hanra Foyer)		
10:30-12:30	CONCURRENT SESSION 7 (Hanra 1) VACCINE PRODUCTION AND EVALUATION Session Chair: Annette Vogel <i>BioNTech, Germany</i> Shan Lu, UMASS Chan Medical School, USA	CONCURRENT SESSION 8 (Hanra 2) NEW VACCINES AGAINST OLD BUGS Session Chair: Michael McCluskie, National Research Council Canada (NRC), Canada Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA	CONCURRENT SESSION 9 (Hanra 3) INNOVATIVE RNA VACCINE TECHNOLOGY Co-Organized with IBS Korea Virus Research Institute Session Chairs: Alexander Bukreyev, University of Texas Medical Branch (UTMB), USA Edward Rybicki, University of Cape Town, South Africa
10:40-11:05	Blood on Chip: an in vitro Innate immune response model for Vaccine Development and Evaluation Cyril Guyard BIOASTER, France	New Technology, Vaccine, and Knowledge from Related Pneumococcal Serotypes Moon Nahm University of Alabama at Birmingham, USA	DegradaBALL-mRNA Vaccine to Advance Vaccine Delivery Against Future Pandemic: The 100 Days Mission Dal-Hee Min Seoul National University, South Korea
11:05-11:20	Development of a Thermostable, Immunogenic ACM Tunable Platform (ATP) for mRNA Delivery Using Amphiphilic Block Co-polymers Jian Hang Lam , ACM Biolabs, China	The Comparison of Plant Virus Nanoparticles in the Presentation of a Conserved Influenza Epitope to Develop a Universal Influenza Vaccine Candidate in Nicotiana Benthamiana Kirti Daya , Biopharming Research Unit, University of Cape Town, South Africa	SARS-CoV-2 Plasma Cells are Largely Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination Doan Nguyen , Emory University, USA
11:20-11:35	Long-Term Immunogenicity of Typhoid Conjugate Vaccine Among Healthy Filipino Adults and Children Rejwana Haque Pial , International Vaccine Institute, South Korea	The Next Generation Influenza Vaccine: mRNA or Recombinant Protein? João Paulo Portela Catani , VIB-UGent Center for Medical Biotechnology, Belgium	A Novel Production Platform for mRNA Vaccines: Encapsulation in a Virus Capsid Protein in Plants Edward Rybicki , University of Cape Town, South Africa

11:35-11:50	Optimization and Scale Up of Suspension Vero Cell Culture Technology Towards Industrial Applications in Cost-Effective Production of Viral Vaccines Lakshmi Krishnan, <i>National Research Council Canada, Canada</i>	Passive Immune Protection Against A(H1N1) pdm2009 Virus Infection with In Vivo-delivered DNA-encoded Influenza H1HA-head and pan-NA Directed Monoclonal Antibodies in a Murine Challenge Model Ami Patel, <i>The Wistar Institute, USA</i>	A Quadrivalent mRNA Vaccine Against HSV-2 Showed the Enhanced Immunogenicity and Protection Against Primary and Latent Infections Youngran Cho, <i>The Catholic University of Korea, South Korea</i>
11:50-12:05	Army Liposome Formulation Containing QS-21 Modulates Proinflammatory Milieu and Innate Anti-viral Factors Rendering Human Monocyte-derived Macrophages Less Permissive to HIV-1 Infection Mangala Rao <i>US Military HIV Research Program, USA</i>	Pan-influenza B Virus Control with Single-Domain Antibodies Directed Against Hemagglutinin and Neuraminidase Xavier Saelens, <i>Ghent University and VIB, Belgium</i>	Novel One-component Ionizable Amphiphilic Janus Dendrimers (IAJD) as a Delivery Platform for Efficient mRNA Vaccine Development Wook-Jin Park, <i>University of Pennsylvania, USA</i>
12:05-12:20	Characterisation of Immune Responses to the rVSVΔG-LASV-GPC Vaccine Candidate in Healthy Adults Marija Zaric, <i>IAVI, Imperial College London, United Kingdom</i>	Novel Rabies Vaccine Offers Potential for Population Wide Pre-exposure Prophylaxis in Rabies Endemic Areas Alexander Douglas, <i>University of Oxford, United Kingdom</i>	mRNA Engineered Antibodies as Immune Therapeutics for Herpes Simplex Virus Associated Diseases Sita Awasthi <i>Perelman School of Medicine, USA</i>
12:30-14:00	LUNCH Sponsored by Valneva Austria GmbH (Hanra 1 & 2)		
12:45-13:45	Canadian Government Workshop: Health Emergency Readiness Canada; Life Sciences and Biomanufacturing Capacity Building and Opportunity for Global Cooperation in Vaccine Development. (Hanra 3) Session Chair: Lakshmi Krishnan, <i>Vice-President, National Research Council Canada</i> Plenary Speaker: Ritu Banerjee, <i>Assistant Deputy Minister, Industry Science Economic Development, Government of Canada</i> Panel Discussion: International Experts		
14:00-14:30	ISV AWARDS CEREMONY (Hanra 1 & 2)		
14:30-14:55	PAPER OF THE YEAR PRESENTATION (Hanra 1 & 2) Session Chair: Linda Klavinskis, <i>King's College London, UK</i> HIV Vaccines Induce CD8+ T Cells with Low Antigen Receptor Sensitivity Mark Connors, NIH/NIAID, USA		
14:55-15:45	PLENARY SESSION 6: VACCINES FOR ONE HEALTH AND PANDEMIC PREPAREDNESS (Hanra 1 & 2) Session Chairs: Barbara Felber, <i>National Cancer Institute, USA</i> Dong Yu, Dynavax Technologies, USA		
14:55-15:20	Jumping Around: Cross-Species Transmission of H5N1 Angie Rasmussen, University of Saskatchewan, Canada		
15:20-15:45	Bridging Veterinary and Human Vaccinology: Correlates of Protection and Post-Vaccination Monitoring for Enhanced Immunization Strategies Alejandra Capozzo, UAI, Argentina		
15:45-15:55	CLOSING SESSION (Hanra 1 & 2) Joon Haeng Rhee, Chonnam National University, South Korea; Margaret Liu, ProTherImmune & Karolinska Institutet, USA & Sweden Shan Lu, UMass Chan Medical School, USA		
15:55-16:00	INTRODUCTION TO 2025 ISV ANNUAL CONGRESS (Hanra 1 & 2) Ed Rybicki, University of Cape Town, South Africa		

ISV EDUCATION & TRAINING ACTIVITIES
All will be held in Rendezvous Room - Second Floor

BRIGHT SPARKS SESSIONS

MONDAY 21 OCTOBER 2024		TUESDAY 22 OCTOBER 2024	
15:30-17:20	BRIGHT SPARKS IN VACCINOLOGY: PhD STUDENTS Session Chairs: Linda Klavinskis, <i>King's College London, UK</i> Jean Boyer, <i>Agenta Therapeutics, USA</i>	10:45-12:25	BRIGHT SPARKS IN VACCINOLOGY: EARLY CAREER RESEARCHERS Session Chairs: Linda Klavinskis, <i>King's College London, UK</i> Frédéric Tangy <i>Oncovita - Institut Pasteur, France</i>
15:30-15:40	Evaluation of an Adjuvanted DNA Vaccine for the Control of Virulent Strains of Newcastle Disease Virus Charlie Amoia <i>Sokoine University of Agriculture, Tanzania</i>	10:45-10:55	Generation and Evaluation of an African Swine Fever Virus Mutant with Deletion of the CD2v and UK Genes Teshale Araya <i>Tigray Agricultural Research Institute, Ethiopia</i>
15:40-15:50	Intention to Receive COVID-19 and Influenza Vaccines During Pregnancy: A Prospective Cross-sectional Study Among Pregnant Women Attending Antenatal Care in Cape Town Imen Ayouni Ep Labidi <i>University of Cape Town, South Africa</i>	10:55-11:05	Understanding the Enhanced Immune Responses to High-Density Microarray Patch Vaccination through Spatial Transcriptomics and Antibody Repertoire Analysis Jovin Choo, <i>University of Queensland, Australia</i>
15:50-16:00	Efficient HBV Immunization Using a Self- Powered Microfluidic Chip for Reconstitution and Intradermal Delivery of CpG-adjuvanted HBs Vaccine Elias Broeckhoven <i>KU Leuven, Belgium</i>	11:05-11:15	Fc-modification of Anti-PcrV Gene-encoded Antibodies Modulates Complement- Mediated Killing of Pseudomonas aeruginosa Jillian Eisenhauer, <i>University of Pennsylvania/The Wistar Institute, USA</i>
16:00-16:10	Development of a Dual Vaccine Against Bovine Coronavirus and Lumpy Skin Disease Virus Nicole Chineka <i>University of Cape Town, South Africa</i>	11:15-11:25	A Phase III Randomized Controlled Multi- Centre Trial to Evaluate the Efficacy of the R21/Matrix-M Vaccine in African Children Against Clinical Malaria Angela Gwakisa, <i>Ifakara Health Institute, Tanzania</i>
16:10-16:20	Cinnamon and Spice as Adjuvants are Nice: Targeting TRP Channels to Boost Mucosal Immunization Madison Davis, <i>The University of Texas at Austin, USA</i>	11:25-11:35	Structural Basis of Broad Protection Against Influenza Virus by a Human Antibody Targeting the Neuraminidase Active Site Through a Recurring Motif in CDR-H3 Gyunghee Jo, <i>The Scripps Research Institute, USA</i>
16:20-16:30	High Throughput Epitope Mapping Using Charge Scanning Mutagenesis Kawkab Kanjo, <i>Indian Institution of Science, India</i>	11:35-11:45	YF17D-vectored COVID-19 Vaccine Protects from SARS-CoV-2-induced Adverse Pregnancy Outcomes in a Hamster Model of COVID-19 Yana Kumpanenko, <i>KU Leuven, Belgium</i>

16:30-16:40	A Two-Component Cocktail of Engineered E Domain III Nanoparticles Elicits Broadly Neutralizing Antibody Responses against Dengue virus in Mice Margaret Mariano, <i>Albert Einstein College of Medicine, USA</i>	11:45-11:55	Targeted Delivery of Immunotherapeutics to the Lower Regions of the Lung: Using One-component Ionizable Amphiphilic Janus Dendrimers to Deliver TGF- β mRNA to the Lung Parenchyma Jaclynn Meshanni, <i>University of Pennsylvania, USA</i>
16:40-16:50	Engineering, Structure, and immunogenicity of a Crimean-Congo Hemorrhagic Fever Virus Pre-fusion Heterotrimeric Glycoprotein Complex Elizabeth McFadden, <i>University of Texas at Austin, USA</i>	11:55-12:05	A Built-in Flagellin Adjuvanted Ferritin Nanocage Mucosal Vaccine Platform Induces High-quality Protective Immune Responses Against Respiratory Infections Tien Duc Nguyen, <i>Chonnam National University, South Korea</i>
16:50-17:00	Novel Adenoviral Vaccine Candidate Against a Century-old Disease: The Ongoing Search for an Efficient Immune-mediated Control of Chagas Disease Sebastian Trinitario, <i>IMPam (UBA-CONICET), Argentina</i>	12:05-12:15	Improving Humoral Immunogenicity of Adenoviral Vector Vaccines by Capsid Display Alexander Sampson, <i>University of Oxford, United Kingdom</i>
17:00-17:10	Preparation and Immunogenicity Study of Novel Hepatitis B Virus-like Particles Weixiao Wang, <i>Nanjing Medical University, China</i>	12:15-12:25	Mapping the Serological Response to Chikungunya Infection and Vaccination Daniel Yara, <i>MHRA, United Kingdom</i>
17:10-17:20	A Novel Bovine TB Vaccine Borne Unexpectedly Out of Basic Mycobacterium Tuberculosis-Complex Virulence Research Slim Zriba, <i>University of Saskatchewan VIDO, Canada</i>		

Continued to Next Page

MENTORSHIP PROGRAM

TUESDAY 22 OCTOBER 2024

12:45-13:30 MENTORSHIP PROGRAM: LEARN ABOUT THE ISV'S NEW PROGRAM
PRESENTERS: Jean Boyer, *Agenta Therapeutics, USA*;
Linda Lua, *The Growth Impact Party Ltd, Australia*

CAREER DEVELOPMENT

WEDNESDAY 23 OCTOBER 2024

12:45-13:45 CAREER DEVELOPMENT: HAVE YOUR QUESTIONS ANSWERED ABOUT DIFFERENT CAREER PATHS
Session Chair: Michael Schotsaert, *Ichan School of Medicine at Mount Sinai, USA*
PANEL:
Barbara Felber, *Head Human Retrovirus Pathogenesis Section, Center for Cancer Research, NCI, Vaccine Branch, USA*
Neil Almond, *Head of the Blood and Tissue Pathogens, Adventitious Agents and Diagnostics group, Division of Virology, NIBSC, UK*
Lars Frelin, *Associate Professor, Director of Education (grundutbildningsansvarig, GUA), Facility Manager at Karolinska Institutet, Sweden*
Alptekin Guler, *Senior Scientist Infectious Disease Vaccines, BioNTech, Germany*